Professor Katie Flanagan, Infectious Diseases Specialist and Clinical Professor at the University of Tasmania, will discuss the platform technologies being used to design COVID-19 vaccines, candidates in preclinical and clinical trials and phase 3 trial efficacy results. She will then discuss the progress globally with COVID-19 vaccine rollout and the Australian COVID-19 strategy and program in more detail. The talk will conclude with discussing next-generation vaccines including those against emerging SARS-CoV-2 variants.